Tevogen Bio Expands AI Collaboration with Microsoft to Accelerate Drug Development

Tevogen Bio Expands AI Partnership with Microsoft

Tevogen Bio Holdings Inc. (NASDAQ: TVGN), a clinical-stage specialty immunotherapy biotech, has announced an expanded collaboration with Microsoft (NASDAQ: MSFT) to accelerate drug development using artificial intelligence (AI) and machine learning (ML) 1

1

2

2

. This partnership aims to revolutionize immunotherapy by integrating Microsoft's AI tools into Tevogen's proprietary PredicTcell technology 3

3

.

AI-Driven Drug Discovery Advancements

Dr. David Rhew, Global Chief Medical Officer & VP of Healthcare at Microsoft, highlighted the transformative impact of AI on drug discovery. He cited an example where AI-powered tools completed a computational task in months that would have traditionally taken "thousands of years" 1

1

. This dramatic reduction in time showcases the paradigm shift AI is bringing to pharmaceutical research and development.

Multimodal Data and Generative AI

The collaboration emphasizes the use of multimodal data AI, which processes information from diverse sources such as imaging, genomics, and electronic health records. Generative AI serves as a powerful query engine on top of these "foundation models," enabling seamless interpretation of complex data into clinically relevant results 1

1

2

2

.

Ensuring Data Quality and Responsible AI

Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, stressed the importance of creating curated datasets supported by wet-lab research to fuel reliable AI models. Both Tevogen and Microsoft emphasized the need for "clean" and "annotated" datasets, likening AI to a powerful engine that requires refined data as fuel 1

1

2

2

.

Expanded Collaboration Details

The broadened partnership will utilize Microsoft's AI, cloud capabilities, and health and life sciences expertise to accelerate Tevogen Bio's target identification and pre-clinical processes. Tevogen will integrate Microsoft's AI tools into Tevogen.AI to expand its pre-clinical pipeline and develop algorithms to decode HLA-T cell interactions 3

3

4

4

.

Market Impact and Future Prospects

Following the announcement, Tevogen Bio's stock surged by 52% in premarket trading, reaching $2.06 4

4

. This significant market reaction underscores investor confidence in the potential of AI-driven drug development.

Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio, stated, "AI is the next industrial revolution and could be humanity's greatest leap yet." He emphasized the company's commitment to advancing affordable medical innovation through the seamless integration of medical science and technology 1

1

2

2

.

As this collaboration progresses, it has the potential to significantly impact the healthcare industry by accelerating the development of precision T cell therapies for infectious diseases, cancers, and neurological disorders, potentially leading to more accessible and personalized treatments for patients.